Marker Therapeutics, Inc. (NASDAQ:MRKR) Sees Large Growth in Short Interest

Marker Therapeutics, Inc. (NASDAQ:MRKR) saw a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 232,100 shares, an increase of 20.0% from the January 15th total of 193,400 shares. Approximately 3.0% of the company’s shares are short sold. Based on an average daily volume of 72,900 shares, the days-to-cover ratio is currently 3.2 days.

Analyst Upgrades and Downgrades

MRKR has been the topic of several recent analyst reports. Brookline Capital Management upgraded shares of Marker Therapeutics to a “strong-buy” rating in a report on Monday, February 10th. LADENBURG THALM/SH SH upped their price objective on shares of Marker Therapeutics from $11.00 to $19.00 and gave the company a “buy” rating in a report on Monday, October 21st.

Insider Buying and Selling

In other Marker Therapeutics news, Director Steve Elms acquired 11,085 shares of Marker Therapeutics stock in a transaction that occurred on Monday, December 23rd. The shares were bought at an average price of $3.20 per share, with a total value of $35,472.00. Following the completion of the purchase, the director now directly owns 325,370 shares in the company, valued at $1,041,184. This trade represents a 3.53 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Enterprise Associates 16 New acquired 554,250 shares of Marker Therapeutics stock in a transaction that occurred on Monday, December 23rd. The stock was acquired at an average cost of $3.20 per share, for a total transaction of $1,773,600.00. Following the purchase, the insider now owns 1,625,678 shares of the company’s stock, valued at $5,202,169.60. The trade was a 51.73 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 17.35% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Marker Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Alyeska Investment Group L.P. bought a new stake in Marker Therapeutics in the 4th quarter worth about $2,847,000. Blue Owl Capital Holdings LP bought a new stake in Marker Therapeutics in the 4th quarter worth about $1,724,000. Aisling Capital Management LP grew its position in shares of Marker Therapeutics by 3.5% during the 4th quarter. Aisling Capital Management LP now owns 325,370 shares of the company’s stock valued at $1,012,000 after acquiring an additional 11,084 shares during the period. LPL Financial LLC bought a new position in shares of Marker Therapeutics during the 4th quarter valued at approximately $248,000. Finally, Northern Trust Corp grew its position in shares of Marker Therapeutics by 66.9% during the 4th quarter. Northern Trust Corp now owns 54,156 shares of the company’s stock valued at $168,000 after acquiring an additional 21,703 shares during the period. Institutional investors and hedge funds own 22.39% of the company’s stock.

Marker Therapeutics Price Performance

Shares of NASDAQ MRKR traded up $0.02 during trading on Monday, hitting $1.72. 61,990 shares of the company traded hands, compared to its average volume of 78,471. Marker Therapeutics has a fifty-two week low of $1.48 and a fifty-two week high of $5.99. The business’s fifty day moving average is $2.81 and its 200 day moving average is $3.18.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.